Cargando…

The cost-effectiveness analysis of serplulimab versus regorafenib for treating previously treated unresectable or metastatic microsatellite instability-high or deficient mismatch repair colorectal cancer in China

OBJECTIVE: The aim of this study was to investigate the cost-effectiveness of serplulimab versus regorafenib in previously treated unresectable or metastatic microsatellite instability-high (MSI-H)/deficient mismatch repair (dMMR) colorectal cancer in China. METHODS: From the perspective of China’s...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ma, Yue, Zhou, Jiting, Ye, Yuxin, Wang, Xintian, Ma, Aixia, Li, Hongchao
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10171919/ https://www.ncbi.nlm.nih.gov/pubmed/37182176 http://dx.doi.org/10.3389/fonc.2023.1113346

Ejemplares similares

Mismatch Repair/Microsatellite Instability Testing Practices among US Physicians Treating Patients with Advanced/Metastatic Colorectal Cancer
por: Eriksson, Jennifer, et al.
Publicado: (2019)

Cost-effectiveness analysis of sintilimab plus bevacizumab biosimilar compared with lenvatinib as the first-line treatment of unresectable or metastatic hepatocellular carcinoma
por: Zhou, Ting, et al.
Publicado: (2022)

A Phase II Study of Avelumab Monotherapy in Patients with Mismatch Repair–Deficient/Microsatellite Instability–High or POLE-Mutated Metastatic or Unresectable Colorectal Cancer
por: Kim, Jwa Hoon, et al.
Publicado: (2020)

Exploration of an alternative reconstructed individual patient data-based approach for budget impact analysis of anticancer drugs
por: Ma, Yue, et al.
Publicado: (2023)

Immune Checkpoint Inhibition in Metastatic Colorectal Cancer Harboring Microsatellite Instability or Mismatch Repair Deficiency
por: Cohen, Romain, et al.
Publicado: (2021)

Phase 2 Study of the PD-1 Inhibitor Serplulimab plus the Bevacizumab Biosimilar HLX04 in Patients with Previously Treated Advanced Hepatocellular Carcinoma
por: Ren, Zhenggang, et al.
Publicado: (2022)

Gynecological Cancers Caused by Deficient Mismatch Repair and Microsatellite Instability
por: Deshpande, Madhura, et al.
Publicado: (2020)

Real‐world data on microsatellite instability status in various unresectable or metastatic solid tumors
por: Akagi, Kiwamu, et al.
Publicado: (2021)

Microsatellite Instability Use in Mismatch Repair Gene Sequence Variant Classification
por: Thompson, Bryony A., et al.
Publicado: (2015)

Relationship of microsatellite instability to mismatch repair deficiency in malignant tumors of dogs
por: Inanaga, Sakuya, et al.
Publicado: (2022)

Advances in immune therapies for the treatment of microsatellite instability-high/deficient mismatch repair metastatic colorectal cancer (Review)
por: Choucair, Khalil, et al.
Publicado: (2021)

Serplulimab, a novel anti-PD-1 antibody, in patients with microsatellite instability-high solid tumours: an open-label, single-arm, multicentre, phase II trial
por: Qin, Shukui, et al.
Publicado: (2022)

Microsatellite instability and mismatch repair gene inactivation in sporadic pancreatic and colon tumours
por: Ghimenti, C, et al.
Publicado: (1999)

Microsatellite instability and mismatch repair protein expressions in lymphocyte‐predominant breast cancer
por: Horimoto, Yoshiya, et al.
Publicado: (2020)

Mismatch Repair Protein Expression and Microsatellite Instability in Cutaneous Squamous Cell Carcinoma
por: Gambichler, Thilo, et al.
Publicado: (2021)

Mismatch repair is a double-edged sword in the battle against microsatellite instability
por: Miller, Carson J., et al.
Publicado: (2022)

Phase II dose titration study of regorafenib in progressive unresectable metastatic colorectal cancer
por: Kato, Takeshi, et al.
Publicado: (2023)

The degree of microsatellite instability predicts response to PD-1 blockade immunotherapy in mismatch repair-deficient/microsatellite instability-high colorectal cancers
por: Wang, Qiao-Xuan, et al.
Publicado: (2021)

Genomic Profiling for KRAS, NRAS, BRAF, Microsatellite Instability, and Mismatch Repair Deficiency Among Patients With Metastatic Colon Cancer
por: Gutierrez, Martin E., et al.
Publicado: (2019)

Non-classical phenotypes of mismatch repair deficiency and microsatellite instability in primary and metastatic tumors at different sites in Lynch syndrome
por: Li, Zhiyu, et al.
Publicado: (2022)

Circulating cytokines and outcome in metastatic colorectal cancer patients treated with regorafenib
por: Ricci, Vincenzo, et al.
Publicado: (2020)

Correction To: Serplulimab, a novel anti-PD-1 antibody, in patients with microsatellite instability-high solid tumours: an open-label, single-arm, multicentre, phase II trial
por: Qin, Shukui, et al.
Publicado: (2022)

Are High Levels of Microsatellite Instability and Microsatellite Stability Identical in DNA Mismatch Repair-Deficient Colorectal Cancer Patients?
por: Qiu, Yan-Yu, et al.
Publicado: (2023)

Patient-reported outcomes in the GARNET trial in patients with advanced or recurrent mismatch repair-deficient/microsatellite instability-high endometrial cancer treated with dostarlimab
por: Kristeleit, Rebecca, et al.
Publicado: (2022)

Efficacy and safety of serplulimab plus nab-paclitaxel in previously treated patients with PD-L1–positive advanced cervical cancer: a phase II, single-arm study
por: An, Jusheng, et al.
Publicado: (2023)

Concordance between microsatellite instability testing and immunohistochemistry for mismatch repair proteins and efficient screening of mismatch repair deficient gastric cancer
por: Yamamoto, Gou, et al.
Publicado: (2023)

Human AP endonuclease suppresses DNA mismatch repair activity leading to microsatellite instability
por: Chang, In-Youb, et al.
Publicado: (2005)

Human AP endonuclease suppresses DNA mismatch repair activity leading to microsatellite instability
por: Chang, In-Youb, et al.
Publicado: (2005)

Pembrolizumab in Asian patients with microsatellite‐instability‐high/mismatch‐repair‐deficient colorectal cancer
por: Yoshino, Takayuki, et al.
Publicado: (2022)

High-sensitivity microsatellite instability assessment for the detection of mismatch repair defects in normal tissue of biallelic germline mismatch repair mutation carriers
por: González-Acosta, Maribel, et al.
Publicado: (2020)

Single‐Agent Regorafenib in Metastatic Colorectal Cancer Patients with Any RAS or BRAF Mutation Previously Treated with FOLFOXIRI plus Bevacizumab (PREVIUM Trial)
por: García‐Alfonso, Pilar, et al.
Publicado: (2018)

Two modes of microsatellite instability in human cancer: differential connection of defective DNA mismatch repair to dinucleotide repeat instability
por: Oda, Shinya, et al.
Publicado: (2005)

Discordance between immunochemistry of mismatch repair proteins and molecular testing of microsatellite instability in colorectal cancer
por: Guyot D'Asnières De Salins, A., et al.
Publicado: (2021)

Retained Mismatch Repair Protein Expression Occurs in Approximately 6% of Microsatellite Instability-High Cancers and is Associated with Missense Mutations in Mismatch Repair Genes.
por: Hechtman, Jaclyn F., et al.
Publicado: (2019)

Efficacy and Safety of Regorafenib Monotherapy among Patients with Previously Treated Metastatic Colorectal Cancer in a Chinese Population: A Real-World Exploratory Study
por: Wang, Rui-Tao, et al.
Publicado: (2021)

The EMA assessment of pembrolizumab as monotherapy for the first-line treatment of adult patients with metastatic microsatellite instability-high or mismatch repair deficient colorectal cancer
por: Trullas, A., et al.
Publicado: (2021)

Mismatch Repair Protein Loss as a Prognostic and Predictive Biomarker in Breast Cancers Regardless of Microsatellite Instability
por: Fusco, Nicola, et al.
Publicado: (2018)

DNA Mismatch Repair Deficiency Detection in Colorectal Cancer by a New Microsatellite Instability Analysis System
por: Wu, Shafei, et al.
Publicado: (2020)

Subcutaneous envafolimab monotherapy in patients with advanced defective mismatch repair/microsatellite instability high solid tumors
por: Li, Jian, et al.
Publicado: (2021)

Saffron and Its Major Ingredients’ Effect on Colon Cancer Cells with Mismatch Repair Deficiency and Microsatellite Instability
por: Amin, Amr, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_vb0i3ahjj5gahj3v4r882ddb68